Related Experiment Video
Updated: Aug 10, 2026
15:45
Cardiac Stress Test Induced by Dobutamine and Monitored by Cardiac Catheterization in Mice
Published on: February 10, 2013
Tailored therapy using dobutamine and nitroglycerin in advanced heart failure
M H Drazner1, M A Solomon, B Thompson
1Division of Cardiology, University of Texas Southwestern Medical Center, Dallas 75235-9047, USA. mdrazn@mednet.swmed.edu
The American Journal of Cardiology
|October 26, 1999
Summary
This study shows that tailored heart failure therapy improved hemodynamic function and reduced hospital readmissions in advanced cases. Patients weaned from inodilator therapy experienced significant benefits.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Advanced heart failure presents significant therapeutic challenges.
- Optimizing hemodynamic parameters is crucial for managing heart failure patients.
Purpose of the Study:
- To evaluate a tailored hemodynamic-goal-oriented therapy for advanced heart failure.
- To assess the efficacy of inodilator therapy followed by oral vasodilators.
Main Methods:
- Initiated therapy with dobutamine and nitroglycerin infusions (for pulmonary hypertension).
- Escalated oral vasodilator doses in patients with advanced heart failure.
- Monitored hemodynamic parameters and 90-day hospital readmission rates.
Main Results:
- 23 out of 29 patients were successfully weaned from inodilator therapy.
- Significant improvements in hemodynamic parameters were observed in successfully treated patients.
- A low 90-day hospital readmission rate was documented.
Conclusions:
- Tailored hemodynamic-goal-oriented therapy is effective for advanced heart failure.
- Inodilator therapy followed by oral vasodilators can lead to improved outcomes.
- This approach may reduce hospital readmissions in heart failure patients.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...